Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
AMBRISENTAN MSN (Accelagen Pty Ltd)
Product name
AMBRISENTAN MSN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
ambrisentan
Registration type
New generic medicine
Indication
AMBRISENTAN MSN (film-coated tablet) is indicated for the treatment of:
- idiopathic pulmonary arterial hypertension (PAH),
- pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD), in patients with WHO functional class II, III or IV symptoms.